Erratum: Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications (BioMed Research International (2021) 2021 (9996193) DOI: 10.1155/2021/9996193)

Brian Godman*, Magdalene Wladysiuk, Stuart McTaggart, Amanj Kurdi, Eleonora Allocati, Mihajlo Jakovljevic, Francis Kalemeera, Iris Hoxha, Anna Nachtnebel, Robert Sauermann, Manfred Hinteregger, Vanda Marković-Peković, Biljana Tubic, Guenka Petrova, Konstantin Tachkov, Juraj Slabý, Radka Nejezchlebova, Iva Selke Krulichová, Ott Laius, Gisbert SelkeIrene Langner, András Harsanyi, András Inotai, Arianit Jakupi, Svens Henkuzens, Kristina Garuolienė, Jolanta Gulbinovič, Patricia Vella Bonanno, Jakub Rutkowski, Skule Ingeberg, Øyvind Melien, Ileana Mardare, Jurij Fürst, Sean Macbride-Stewart, Carol Holmes, Caridad Pontes, Corinne Zara, Marta Turu Pedrola, Mikael Hoffmann, Vasileios Kourafalos, Alice Pisana, Rita Banzi, Stephen Campbell, Bjorn Wettermark

*Corresponding author for this work

Research output: Contribution to journalComment/debate

Abstract

In the article titled “Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications” [1], the captions of Figures 3 and 4 were incorrect. The corrected captions for Figures 3 and 4 appear below. (Figure Presented). Figure 4: Utilisation of insulin glargine biosimilar (100 IU/ml) as a % of total insulin glargine 100 IU/ml (DDD based) over time across Europe.

Original languageEnglish
Article number9757348
JournalBioMed Research International
Volume2023
DOIs
Publication statusPublished - 2023

Fingerprint

Dive into the research topics of 'Erratum: Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications (BioMed Research International (2021) 2021 (9996193) DOI: 10.1155/2021/9996193)'. Together they form a unique fingerprint.

Cite this